Professor Li is an esteemed medical oncologist with over 20 years of clinical experience, specializing in gastrointestinal tract cancer. Her expertise extends to various types of gastrointestinal cancers, including intestinal cancer, gastric cancer, esophageal cancer, pancreatic cancer, bile duct cancer, and gastroenteropancreatic neuroendocrine tumors. Additionally, she is actively involved in the clinical and translational research of colorectal liver metastases. In 2007 and 2009, she had the opportunity to undergo a short-term training specializing in the treatment of colorectal cancer patients with liver metastases at Hôpital Paul-Brousse (France) and the Mayo Clinic (US) in 2007 and 2009, respectively. Moreover, she has presided and participated in many projects of the National Natural Science Foundation of China, the Guangdong Provincial Natural Science Foundation, and the Collaborative Innovation Project of Guangzhou. She has published over 100 papers, including over 45 SCI papers as first author or corresponding author in reputable journals such as Annals of Oncology, Clinical Cancer Research, and JAMA Netw Open. Notably, she is one of the key contributors to the "Research and Application of Individualized Treatment for Colorectal Cancer" project, which received the second Prize of the National Science and Technology Progress in 2016, First Prize of the China Science and Technology Award in 2015, and the First Prize of Science and Technology Progress of Guangdong Province in 2015.

Professor Li specializes in utilizing internal medicine, including chemotherapy, targeted therapy, and immunotherapy, to treat gastrointestinal tumors. In recent years she has directed her focus towards the clinical and translational research of colorectal liver metastases. This specific area of research is of utmost importance, as colorectal cancer patients with liver metastases pose unique challenges and require specialized treatment approaches.

1986/9-1991/7, Bengbu Medical College, Clinical Medicine, Bachelor
1994/9-1997/7, Sun Yat-sen University of Medical Sciences, Cancer Center, Postgraduate, Oncology
1999/9-2003/7, Sun Yat-sen University Cancer Center, PhD
1991/7-1994/9, Anhui Provincial Hospital, Department of Internal Medicine, Residency
1997/7-1999/12, Sun Yat-sen University of Medical Sciences, Cancer Center, Department of Medical Oncology, Residency
1999/12-2005/12, Sun Yat-sen University Cancer Center, Department of Medical Oncology, Attending Physician
2005/12-2011/12, Sun Yat-sen University Cancer Center, Department of Medical Oncology, Associate Professor, Associate Chief Physician
2011/12-2018/12, Sun Yat-sen University Cancer Center, Department of Medical Oncology, Chief Physician
2018/12-Present, Sun Yat-sen University Cancer Center, Department of Medical Oncology, Professor

1.Luo HY, Li YH, (Contributed equally), et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann of Oncol.2016: 27: 1074. IF: 51.769
2.Ye LF, Li YH (Corresponding Author) et al. Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA. Drug Resist Updat. 2022 Sep 29;65:100883. IF: 22.841
3.Li YH, Wang F, et al. EGFR FISH Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients. Clin Cancer Res.2011: 15; 17(2):382 IF: 13.801
4.Wen L, Li YH (Corresponding Author), et al. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation. J Immunother Cancer, 2022, 10(7): e004487. IF: 12.469
5.Wang DS, Li YH (Corresponding Author), et al. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Theranostics, 2021, 11(14): 7018-28. IF: 11.6
6.Wang ZQ, Li YH (Corresponding Author), et al. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Commun (Lond), 2019, 39(1): 26. IF: 15.283
7.Wang DS, Li YH (Corresponding Author), et al. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. JAMA Netw Open, 2021, 4(4): e215250. IF: 13.353
8.Liang JY, Li YH (Corresponding Author), et al. A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma. Int J Biol Sci, 2020, 16(13): 2430-41. IF: 10.75
9.Hu MT, Li YH (Corresponding Author) et al. Delineating the molecular landscape of different histopathological growth patterns in colorectal cancer liver metastases. Front Immunol. 2022; 13: 1045329. IF: 6.429
10.Chen XX, Li YH (Corresponding Author), et al. Circulating PD-L1 is associated with T-cell infiltration and predicts prognosis in patients with CRLM following hepatic resection [J]. Cancer Immunol Immunother, 2022, 71(3): 661-74. IF: 6.63
11.Liang JY, Li YH (Corresponding Author), et al. Histopathological growth patterns correlate with the Immunocore in colorectal cancer liver metastasis patients after hepatectomy. Cancer Immunol Immunother, 2020, 69(12): 2623-34. IF: 6.63
12.Wang Y, Li YH (Corresponding Author), et al. The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases. Cancer Immunol Immunother. 2017 2018, 67(3):435-444. IF: 6.63
13.Wang Y, Li YH (Corresponding Author), et al. A Prehepatectomy Circulating Exosomal microRNA Signature Predicts the Prognosis and Adjuvant Chemotherapeutic Benefits in Colorectal Liver Metastasis. Cancers (Basel), 2021, 13(17):4258. IF: 6.575
14.An X, Li YH (Corresponding Author), et al. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. Cancer. 2014 Mar 1; 120(5):675. IF: 6.921

15.Wang FH, Li YH (Corresponding Author), et al. Efficacy and safety of recombinant human lymphotoxin-alpha derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial. Cancer. 2017, 123: 3986. IF: 6.921

Updated by International Office, Sun Yat-sen University Cancer Center